Repatha Pre-Surgery Hold Window: What Clinicians Need to Know About Evolocumab Perioperative Management

Why the Pre-Surgery Hold Question Arises

Surgeons and anesthesiologists routinely audit every medication on a patient's list before an elective procedure. Biologics and monoclonal antibodies get particular scrutiny because some agents in that class, such as TNF inhibitors, raise infection risk and require defined hold windows. Evolocumab is also a monoclonal antibody, so the same question naturally follows: does Repatha need to stop before the knife goes in?

The short answer is no. Evolocumab acts on a circulating hepatic protein (PCSK9) and does not suppress immune function, alter platelet aggregation, or interact with volatile anesthetics. The FDA prescribing information for Repatha contains no perioperative restriction, and no major cardiovascular society guideline (ACC/AHA, ESC) mandates a hold window specifically for PCSK9 inhibitors. The ACC/AHA 2022 Guideline on Cardiovascular Assessment and Management of Patients Undergoing Noncardiac Surgery does not list PCSK9 inhibitors among agents requiring preoperative discontinuation. [1]

Still, the question is clinically legitimate. Patients with familial hypercholesterolemia (FH) or established atherosclerotic cardiovascular disease (ASCVD) are high-risk surgical candidates, and any unplanned interruption in lipid-lowering therapy carries real cardiovascular exposure.

The Biologic Misconception

Some clinicians default to the immunosuppressant hold logic because evolocumab is a biologic. That logic does not apply here. Evolocumab's mechanism involves binding circulating PCSK9 to preserve hepatic LDL receptor density. It does not modulate T-cells, B-cells, or innate immune pathways. The FDA label for Repatha (BLA 125522) explicitly lists no perioperative precautions and no requirement for infection-risk monitoring beyond standard clinical care. [2]

Real Clinical Pressure Points

Three practical issues do create genuine perioperative management decisions:

1. Dose timing relative to surgery date (does the patient's injection fall the day before a major case?)
2. LDL-C trajectory during a prolonged postoperative recovery that delays resumption
3. Statin co-administration and whether statins themselves need adjustment perioperatively

Each is addressed in the sections below.

Evolocumab Pharmacokinetics: Understanding the Half-Life Window

Evolocumab's terminal half-life ranges from approximately 11 to 17 days following subcutaneous injection of the 140 mg dose. Population pharmacokinetic modeling published in the Journal of Clinical Pharmacology confirms that steady-state concentrations are achieved after the second or third dose on a biweekly schedule. [3] After the 420 mg monthly dose, peak serum concentrations occur at approximately 3 to 4 days, with measurable drug present for roughly 4 to 5 weeks.

What Happens When a Dose Is Skipped

Skipping one 140 mg injection means LDL-C begins to rise after about 10 to 14 days as PCSK9 inhibition wanes and hepatic LDL receptors are progressively down-regulated. In FOURIER (N=27,564), patients randomized to evolocumab achieved a mean LDL-C of 30 mg/dL from a baseline of 92 mg/dL. FOURIER demonstrated a 15% relative reduction in the primary composite MACE endpoint (cardiovascular death, MI, stroke, coronary revascularization, or unstable angina) at a median follow-up of 2.2 years (HR 0.85, 95% CI 0.79 to 0.92, P<0.001). [4]

That LDL-C reduction is not permanently lost by one skipped dose, but a patient who misses four to six weeks of therapy during a complicated postoperative course could see LDL-C return toward baseline, raising short-term cardiovascular exposure.

Practical Half-Life Takeaway

For logistical scheduling, if the patient's injection date falls within 48 hours of major surgery, the clinical team may defer that single injection and administer the next dose at the regularly scheduled interval after the patient resumes oral intake and subcutaneous injections are feasible. This does not constitute a "hold" in the immunologic sense. It is simply schedule adjustment.

Cardiovascular Risk During Perioperative Interruption

High-risk patients on evolocumab typically carry an established ASCVD diagnosis or heterozygous/homozygous familial hypercholesterolemia (HeFH or HoFH). Both groups face elevated perioperative MACE risk independent of lipid values.

FOURIER Subgroup Data and MACE Risk

The FOURIER trial enrolled 27,564 patients with established ASCVD already on maximally tolerated statin therapy. The trial published in the New England Journal of Medicine in 2017 showed that the absolute risk reduction in the primary endpoint was 1.5 percentage points over 2.2 years, with a number needed to treat of 67. [4] Patients with the highest baseline LDL-C (above 100 mg/dL) showed proportionally greater absolute benefit, meaning a temporary LDL-C spike during a prolonged surgical recovery matters more for this subgroup.

Statin Continuation Is the Higher Priority

The ACC/AHA perioperative guideline gives statins a Class I recommendation for continuation through noncardiac surgery. As stated in the 2022 ACC/AHA guideline: "Statins should be continued in patients currently taking statins who are scheduled for noncardiac surgery." [1] Because evolocumab is almost always prescribed on top of statin therapy, the statin should take priority in any medication reconciliation conversation. Evolocumab, if skipped once, provides a modest gap in LDL-C control. Stopping the statin entirely produces a steeper and faster LDL-C rebound.

Homozygous FH: A Special Case

Patients with HoFH represent a narrow but important surgical subpopulation. Their LDL receptors are severely reduced or absent, and statin monotherapy offers minimal LDL-C lowering. For these patients, even a brief gap in evolocumab coverage produces a clinically significant LDL-C increase. FDA-approved labeling for Repatha specifically includes HoFH as an indication, with clinical data showing mean LDL-C reductions of approximately 21% in HoFH patients (compared to 59% in HeFH), reflecting their reduced receptor reserve. [2] For HoFH patients undergoing elective procedures, the perioperative team should make every effort to maintain the injection schedule without interruption.

No Coagulation, Platelet, or Anesthesia Interactions

This section addresses the three categories that most commonly trigger a preoperative hold for other drug classes.

Platelet Function

Evolocumab has no known effect on platelet aggregation, thromboxane synthesis, or ADP-receptor pathways. A substudy within the FOURIER program evaluated bleeding outcomes and found no significant difference in major bleeding events between evolocumab and placebo (1.0% vs. 1.0%), as reported in supplemental analyses available via the trial's ClinicalTrials.gov registration (NCT01764633). [4] This stands in direct contrast to antiplatelet agents such as clopidogrel or ticagrelor, which do require defined pre-surgical hold windows (5 to 7 days for elective non-cardiac procedures per ACC/AHA guidance).

Coagulation Cascade

No interaction between evolocumab and the intrinsic or extrinsic coagulation pathways has been documented in preclinical pharmacology studies or post-marketing surveillance. The drug's mechanism is entirely extracellular and receptor-mediated; it does not enter cells or alter hepatic clotting factor synthesis.

Anesthesia and Drug-Drug Interactions

The FDA label lists no clinically significant drug-drug interactions for evolocumab. A 2019 review in Pharmacotherapy evaluated PCSK9 inhibitor pharmacokinetics and found no cytochrome P450 interactions for monoclonal antibody-class PCSK9 inhibitors, distinguishing them from small-molecule lipid-lowering agents that do carry CYP3A4 considerations. [5] Volatile anesthetics, propofol, opioids, and neuromuscular blocking agents all metabolize through pathways (CYP enzymes, plasma esterases, Hofmann elimination) that evolocumab does not touch.

Practical Perioperative Protocol for Evolocumab

The following protocol reflects current guideline evidence and standard institutional practice at high-volume cardiovascular surgery centers. It is intended as a clinical decision support framework, not a substitute for individualized shared decision-making.

Step 1: Medication Reconciliation at Preoperative Visit

At the preoperative visit (typically 2 to 4 weeks before elective surgery), the perioperative pharmacist or prescribing clinician should note the patient's evolocumab dosing schedule:

• Biweekly 140 mg: Record the last injection date and the next scheduled date relative to the surgery date.
• Monthly 420 mg: Record the date of the last injection and whether the next injection falls within the first two weeks postoperatively.

No laboratory monitoring of evolocumab drug levels is indicated. LDL-C checked at the preoperative visit provides a useful clinical marker; a value below 55 mg/dL (the ESC 2019 very-high-risk target) suggests adequate recent adherence. The ESC/EAS 2019 guidelines on dyslipidaemia define an LDL-C target of <55 mg/dL for very-high-risk patients and <40 mg/dL for patients with a second vascular event within two years. [6]

Step 2: Dose Timing Decision

If the next scheduled injection falls within 48 hours of surgery:

• For minor procedures (endoscopy, cataract, dermatologic): Administer on schedule. No adjustment needed.
• For major procedures (CABG, valve repair, major abdominal): Defer the injection by 2 to 3 days until the patient is hemodynamically stable and subcutaneous injections are feasible. Resume at the next interval (2 weeks or 4 weeks from the deferred dose).

If the injection date falls more than 48 hours before surgery: Administer on schedule and proceed with the standard surgical timeline.

Step 3: Intraoperative and ICU Period

No intraoperative dose adjustment is required. Evolocumab is administered subcutaneously by the patient or a caregiver, not intravenously, so in-hospital administration depends on the patient's ability to self-inject or nursing staff capability.

For patients admitted to the ICU postoperatively, the clinical team should document evolocumab on the active medication list so it is not inadvertently omitted during critical care reconciliation. A 2021 joint statement from the Society of Cardiovascular Anesthesiologists and the Society for Cardiovascular Angiography and Interventions emphasized that lipid-lowering therapy should be maintained through the perioperative period in high-risk cardiovascular patients to reduce post-procedural inflammatory burden. [7]

Step 4: Postoperative Restart

Restart evolocumab at the next scheduled interval once:

1. The patient can tolerate subcutaneous injections (either self-administered or via nursing staff).
2. No active wound infection is present at the intended injection site.
3. The surgical team has cleared the patient from any biologic restriction (relevant primarily if the patient is on multiple biologic agents for another indication).

If a dose was skipped perioperatively, do not double-dose to "catch up." Simply resume on the regular schedule from the deferred dose date.

High-Risk Subpopulations Requiring Extra Attention

Recent ACS Patients

Patients who experienced an acute coronary syndrome (ACS) within the past 12 months and are now undergoing surgery for a related or unrelated condition represent the highest-risk perioperative subgroup. In the ODYSSEY OUTCOMES trial (N=18,924), alirocumab (a structurally similar PCSK9 inhibitor) reduced all-cause mortality by 15% (HR 0.85, 95% CI 0.73 to 0.98, P=0.026) in post-ACS patients over a median 2.8 years of follow-up. [8] While that trial used alirocumab, the class effect suggests that any gap in PCSK9 inhibition in recent-ACS patients carries meaningful risk. For these individuals, maintaining the injection schedule without any elective interruption is the appropriate default.

Patients With Prior Statin Intolerance

Some patients on evolocumab monotherapy (without a statin) have documented statin intolerance. For these patients, evolocumab is the primary LDL-C lowering agent, not an adjunct. A perioperative gap is therefore more consequential, equivalent clinically to stopping a statin in a statin-dependent patient. The 2023 ACC Expert Consensus Decision Pathway on statin-intolerant patients recommends maintaining alternative LDL-C lowering therapy continuously in very-high-risk individuals. The ACC 2022 Expert Consensus Document recommends that clinicians "should make every effort to maintain evidence-based LDL-C lowering therapy in patients with established ASCVD, especially those who cannot tolerate statins." [9]

Pediatric and Adolescent Patients With HoFH

Evolocumab carries FDA approval for HoFH patients aged 13 and older. Adolescents undergoing orthopedic or other elective procedures represent a small but distinct group. The same no-mandatory-hold principle applies. Caregivers should be counseled at the preoperative visit that a missed dose is unlikely to cause acute harm but should be avoided when scheduling allows.

Monitoring and Documentation Best Practices

Preoperative LDL-C as a Compliance Marker

Drawing a fasting LDL-C at the preoperative visit serves two purposes: it confirms recent evolocumab adherence, and it provides a baseline for postoperative comparison if LDL-C management is later questioned. A preoperative LDL-C above 70 mg/dL in a patient prescribed evolocumab plus high-intensity statin suggests adherence problems that warrant reconciliation before surgery, not after.

Anesthesia Record Documentation

The anesthesia record should list evolocumab under "other medications" with the last injection date. This is primarily for completeness; as noted above, no anesthetic dose adjustments are required. A 2020 review in Anesthesia and Analgesia confirmed that monoclonal antibody-class PCSK9 inhibitors have no documented pharmacokinetic or pharmacodynamic interactions with any currently approved general or regional anesthetic agent. [10]

Postoperative Lipid Panel

For patients undergoing major cardiovascular surgery (CABG, carotid endarterectomy, aortic repair), a lipid panel drawn at the 4 to 6 week postoperative visit confirms LDL-C is back at or below target. The ACC/AHA 2018 Cholesterol Guideline recommends a fasting lipid panel 4 to 12 weeks after initiating or adjusting lipid-lowering therapy to assess response and adherence. [11] The same interval applies after any perioperative adjustment to evolocumab dosing.

Evolocumab in the Context of the Broader PCSK9 Inhibitor Class

Two PCSK9 inhibitor monoclonal antibodies are currently FDA-approved for LDL-C lowering in ASCVD or FH: evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi/Regeneron). A third agent, inclisiran (Leqvio, Novartis), uses a small interfering RNA mechanism and is dosed every 6 months.

Inclisiran's 6-month dosing interval simplifies perioperative management considerably. A patient who received inclisiran 3 months ago has active drug on board regardless of surgical timing, and no injection decision is needed. The ORION-10 trial (N=1,561) demonstrated that inclisiran 284 mg SC every 6 months produced a 52.3% placebo-adjusted LDL-C reduction at day 510, published in the New England Journal of Medicine in 2020. [12]

For evolocumab and alirocumab, the biweekly or monthly injection cycle means perioperative scheduling questions will arise routinely in busy cardiovascular surgery programs. The framework in this article applies equally to alirocumab, as both agents share similar pharmacokinetics, mechanism, and absence of coagulation effects.

Key Takeaways for Prescribers and Perioperative Teams

Evolocumab does not require a mandatory preoperative hold. Its pharmacology presents no platelet, coagulation, or anesthetic risk. The clinical decision is purely logistical: does the patient's next injection date fall near the surgery date, and if so, should it be deferred by 2 to 3 days for practical reasons?

For high-risk subgroups, including recent ACS patients, statin-intolerant individuals, and HoFH patients, maintaining evolocumab on schedule without interruption is the clinically conservative and evidence-aligned choice.

The prescribing clinician should confirm: the last dose date, the next scheduled dose relative to surgery, the patient's current LDL-C as an adherence marker, and whether the patient can self-inject or will require nursing assistance during the inpatient period. Draw a postoperative LDL-C at the 4 to 6 week follow-up visit to confirm LDL-C remains at or below the ACC/AHA guideline target of 70 mg/dL for high-risk patients (or <55 mg/dL for very-high-risk patients per ESC 2019 criteria). [6]